Sandeep Gupta, MD
Pulmonary Disease · Houston, TXNPI 1063500353
Payments from drug & device makers
Across 648 payments — averaging $1696.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$765K
- AstraZeneca$129K
- Johnson & Johnson$93K
- Verona Pharma, Inc.$68K
- GSK$22K
- Insmed, Inc.$7K
- plus $14K from 31 others
What the payments were for
- Consulting fees$4,4034%
- Speaking & faculty fees$95,12081%
- Travel & lodging$7,5506%
- Food & beverage$10,7799%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 144 | $765,464 |
| AstraZeneca | 75 | $128,750 |
| Johnson & Johnson(2 entities) | 94 | $93,322 |
| Verona Pharma, Inc. | 17 | $68,201 |
| GSK | 125 | $22,470 |
| Insmed, Inc. | 45 | $6,851 |
| Grifols USA, LLC | 20 | $5,973 |
| Boehringer Ingelheim | 26 | $3,272 |
| Abbott | 31 | $3,114 |
| Sanofi | 14 | $572 |
| Regeneron Healthcare Solutions, Inc. | 12 | $301 |
| Intuitive Surgical | 1 | $123 |
| Itamar Medical Inc | 1 | $106 |
| Optinose US, Inc. | 4 | $79 |
| Mylan Specialty L.p. | 3 | $78 |
| Pfizer | 4 | $71 |
| Electromed, Inc. | 3 | $57 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Shionogi Inc | 3 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $42 |
| Novartis | 2 | $33 |
| Resmed Corp | 2 | $32 |
| Philips North America LLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Pulmonx Corporation | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Amgen | 1 | $23 |
| Merck | 1 | $22 |
| AbbVie | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Harmony Biosciences LLC | 1 | $20 |
| Ambu Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$91,402
- Arikayce$4,564
- Prolastin-C Liquid$3,840
- ENSITE PRECISION$2,429
- Prolastin-C$1,800
- AIRSUPRA$240
- SURGIFLO Hemostatic Matrix$145
- BREZTRI$138
- Da Vinci Surgical System$123
- TRELEGY ELLIPTA$121
- WatchPATONE$106
How this compares
$1,099,381 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 356 | $384,270 |
| OfevNintedanib Esylate | 24 | $321,119 |
| Breo ElliptaFluticasone/Vilanterol | 116 | $74,312 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $57,527 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $30,708 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $29,192 |
| EliquisApixaban | 21 | $21,863 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $12,989 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $11,855 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 219 | $6,531 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $5,886 |
| Ventolin HfaAlbuterol Sulfate | 32 | $2,704 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,905 |
| Azithromycin | 212 | $1,128 |
| Prednisone | 177 | $719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $22,470 | $487,774510 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat | $3,272 | $363,68261 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $128,750 | $70,51697 claims |
| PfizerEliquis | $71 | $21,86321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
- Tara BartoHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.